Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
- Drug Discovery
- Diabetes Treatment
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 263763
Licensor grants to Licensee, to the extent Licensor is legally able to do so, a non-exclusive, sublicensable, license in the Territory under such issued letters patent for Licensee to develop, make, have made, use, sell, offer for sale or import Compounds and Products in the Territory.
For the Covenants/Companion Diagnostic, Licensor grants a non-exclusive license, with the right to grant sublicenses, under Licensor Patent Rights, Licensor Know-How, and Companion Diagnostic Trademarks to market and promote the Companion Diagnostic in the Field in the Territory for use in connection with the Product and use the Companion Diagnostic in any way necessary or reasonably useful in order for Licensee to exercise the license granted by Licensor.
This agreement is to develop and commercialize a novel investigational therapeutic candidate vintafolide (EC145).
Vintafolide is a proprietary, injectable, conjugate consisting of folate (vitamin B9) linked to a potent vinca alkaloid chemotherapy agent, desacetylvinblastine monohydrazide (DAVLBH).
Etarfolatide is a folate-targeted molecular imaging agent that is being developed as a noninvasive method to identify tumors that over-express folate receptors.
Product(s) means any pharmaceutical or biological preparation.
Vintafolide is designed to preferentially target the chemotherapy agent to fast growing cancer cells that actively take up folate via the folate receptor. The folate receptor is expressed in a wide variety of cancers including ovarian, NSCLC, breast, colon and kidney.
IPSCIO Record ID: 203246
Method of Enhanced Transmembrane Transport of Exogenous Molecules (continuation of P-88080 now abandoned) (biotin, riboflavin) (CIP of 07/331,816, 4/30/89 ABAN) Patent No. 5,108,921
Method of Enhanced Transmembrane Transport of Exogenous Molecules (folate) U.S. Patent No. 5,416,016
Method of Enhanced Transmembrane Transport of Exogenous Molecules (thiamin) U.S. Patent No. 5,635,382
Method for Targeting a Diagnostic Agent to Cells (no transmembrane transport required) U.S. Patent No. 5,820,847
Composition and Method for Tumor Imaging U.S. Patent No. 5,688,488
Folic Acid Derivatives U.S. Nationalized PCT filed 4/17/00
Method of Treatment Using Lignad-Immunogen Conjugates
IPSCIO Record ID: 371877
X-111 is an advanced, targeted liposomal formulation of Doxorubicin, one of the worldâ€™s most widely used chemotherapies. The specific 2X-111 formulation, which exploits a glutathione enhanced PEG-liposomal delivery system, it may allow 2X-111 to cross the blood-brain barrier (BBB), thereby potentially enabling the treatment of primary brain tumors, such as glioblastoma multiforme (GBM), and secondary brain tumors that originated from cancers outside the brain, such as metastatic breast cancer.
DRPÂ® is a predictive biomarker platform to generate drug-specific companion diagnostics. it is used as a companion diagnostics platform to advance therapeutic candidates by targeting and evaluating patient sub-populations having gene signatures, determined by the DRPÂ® companion diagnostics platform, that will potentially correlate with drug efficacy and patient response to treatment.
IPSCIO Record ID: 330686
Also included is a grant back If this Licensor desires to develop, manufacture, exploit, import, use, offer for sale or sell any Companion Diagnostic on its own or with or through any Affiliate or Third Party, it will send written notice thereof to Licensee, and, if Licensee chooses not to develop, then Licensor shall be granted any associated rights to do so.
Companion Diagnostics means any diagnostic product or biomarker arising from work performed by Licensor pursuant to the terms of this Agreement or otherwise derived from or based in whole or in part on Licensees Intellectual Property.
Discovery Product means a pre-clinical Licensed Product identified through a Screening Assay which possesses desirable properties of a therapeutic or prophylactic agent for the treatment of a clinical condition based on in vitro studies.
Therapeutic Product means an agent with prophylactic or therapeutic activity for the prevention and/or treatment of cancer, developed, in whole or in part, from a Discovery Product and intended to be used, or is used, to treat cancer in humans.
Licensee Patent Rights include
– FGFR1/2 IIIc in NSCLC resistant to erlotinib.
– FGFRviii in glioblastoma.
MIT Patent Rights include
– Alternatively Spliced mRNA lsoforms as Prognostic Indicators for Metastatic Cancer.
Licensees therapeutic focus targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer.
IPSCIO Record ID: 299281
University also grants the right to enter into sublicensing agreements under the Patent Rights.
Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents.
KOS-1584 is our epothilone anticancer clinical candidate that is being evaluated in dose-escalating Phase 1 clinical trials in patients with solid tumors.
IPSCIO Record ID: 238987
The Canadian Licensor grants to Licensee an exclusive sublicense, even as against the Licensor, under the Patent Rights to develop and have developed, market and have marketed, sell and have sold, distribute and have distributed, and manufacture and have manufactured, the Licensed Products in the Territory, said license to include the right to further sub-license.
Licensed Product shall mean anhydrovinblastine sulfate (AVLB), with the chemical name 3 ,4 – dehydrovinblastine sulphate and molecular formula C4Jls~40s-H2SO4â€¢.
KRX-0403 is a novel spindle poison in the vinca alkaloid class of drugs. Derived from the periwinkle plant, the family of vinca alkaloids and the mechanistically similar family of taxanes include some of the most successful cancer drugs ever developed, including NavelbineÂ®, TaxolÂ® and TaxotereÂ®. Although these agents have been widely prescribed, they can be very toxic and may cause varying degrees of neurotoxicity and/or bone marrow suppression. We believe that an equally or more effective but less toxic therapy would satisfy a substantial need for these patients. In a number of pre-clinical animal studies of human cancers, including non-small cell lung cancer, KRX-0403 demonstrated greater anti-cancer activity and lower toxicity than currently marketed vinca alkaloids. In a Phase I clinical trial designed to evaluate the safety, toxicity profile and pharmacokinetics of KRX-0403 in patients with different tumor types, including lung cancer, breast cancer, sarcoma and colon cancer, KRX-0403 was demonstrated to be safe in humans with reversible and manageable toxicities. We believe KRX-0403 may have utility in the treatment of breast, lung and other forms of cancer. We plan to conduct additional dosing clinical trials for KRX-0403.